Search results
Former Pfizer Worker’s 401(k) Account Won’t Be Given to Ex-Wife
Bloomberg Law· 17 hours agoemployee can’t access his 401(k) account to satisfy a $75,000 judgment against him in a defamation lawsuit, a Pennsylvania federal judge said. Judge Juan R. Sánchez rejected her request with ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 13 hours agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 1 day agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 3 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 2 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Sarepta Jumps After Rival Gene Therapy From Pfizer Flops
Investor's Business Daily· 1 day agoThe news gives Sarepta Therapeutics (SRPT) an edge heading to June 21, when the Food and Drug Administration will decide whether to fully approve Elevidys for patients with the muscle-wasting ...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 3 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 18 hours agoThis week, an FDA advisory committee unanimously recommended approval of Eli Lilly’s LLY Alzheimer's...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 2 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...